Measurement of Non-Vitamin K antagonist oral anticoagulants in patient plasma using heptest-STAT coagulation method

Therapeutic Drug Monitoring

Volumn 37, Issue 3, 2015, Pages 375-380

  Du, Shanshan ^a   Harenberg, Job ^a   Krämer, Sandra ^a   Krämer, Roland ^a   Wehling, Martin ^a   Weiss, Christel ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

apixaban; coagulation assay; dabigatran; oral anticoagulants; rivaroxaban

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A; DABIGATRAN ETEXILATE; RIVAROXABAN; THROMBIN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DEXTRO PHENYLALANYLPIPECOLYLARGININE 4 NITROANILIDE; DIPEPTIDE; PYRAZOLE DERIVATIVE; PYRIDONE DERIVATIVE; VITAMIN K GROUP;

ARTICLE; BLOOD CLOTTING TEST; BLOOD CLOTTING TIME; CHROMOGENIC SUBSTRATE ASSAY; COMPARATIVE STUDY; DIRECT THROMBIN INHIBITOR ASSAY; DRUG BLOOD LEVEL; HEMATOLOGY TEST KIT; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; S2238 CHROMOGENIC ASSAY; ANTAGONISTS AND INHIBITORS; BLOOD; BLOOD CLOTTING; DRUG EFFECTS; ENZYME ASSAY; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ANTITHROMBINS; BLOOD COAGULATION; DABIGATRAN; DIPEPTIDES; ENZYME ASSAYS; FACTOR XA INHIBITORS; PYRAZOLES; PYRIDONES; RIVAROXABAN; VITAMIN K; WHOLE BLOOD COAGULATION TIME;

EID: 84929949099     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000157     Document Type: Article

References (42)

1. Husted S, De Caterina R, Andreotti F, et al. Non-vitamin K antagonist oral anticoagulants (NOACs): no longer new or novel. Thromb Haemost. 2014;111:781-782.
2. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic the rapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e278S-325S.
3. Kearon C, Akl EA, Comerota AJ, et al. Antit hrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e419S-494S.
4. Camm AJ , Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace. 2012;14:1385-1413.
5. Calkins H, Kuck KH, Cappato R, et al. 2012 HRS/EHRA/ECAS Expert Consensus Statement on Catheter and Surgical Ablation of At rial Fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Europace. 2012;14:528-606.
6. Samama MM, Contant G, Spiro TE, et al. Laboratory assessment of rivaroxaban: a review. Thromb J. 2013;11:11.
7. Lindhoff-Last E, Ansell J, Spiro T, et al. Laboratory testing of rivaroxaban in routine clinical practice: when, how, and which assays. Ann Med. 2013;45:423-429.
8. Harenberg J, Marx S, Erdle S, et al. Determination of the anticoagulant effects of new oral anticoagulants: an unmet need. Expert Rev Hematol. 2012;5:107-113.
9. Rohde G. Determination of rivaroxaban-A novel, oral, direct Factor Xa inhibitor-in human plasma by high-performance liquid chromatographytandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;872:43-50.
10. Raghavan N, Frost CE, Yu Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos. 2009;37:74-81.
11. Delavenne X, Moracchini J, Laporte S, et al. UPLC MS/MS assay for routine quantification of dabigatran-A direct thrombin inhibitor-in human plasma. J Pharm Biomed Anal. 2012;58:152-156.
12. Gous T, Couchman L, Patel JP, et al. Measurement of the direct oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in human plasma using turbulent flow liquid chromatography with highresolution mass spectrometry. Ther Drug Monit. 2014;36:597-605.
13. Samama MM, Martinoli JL, LeF lem L, et al. Assessment of laboratory assays to measure rivaroxaban-An oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825.
14. Becker RC,Yang H,Barrett Y,et al. Chro mogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-An oral, direct and selective factor Xa inhibitor J Thromb Thrombolysis 2011, 32, 183-187.
15. Harenberg J, Marx S, Wei ss C, et al. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban. J Thromb Haemost. 2012;10:1433-1436.
16. van Ryn J, Stangier J , Haertter S, et al. Dabigatran etexilate-A novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103:1116-1127.
17. Rodgers R, Bagot CN, Lawrence C, et al. Correlating prothrombin time with plasma rivaroxaban level. Br J Haematol. 2013;163:685-687.
18. Patel JP, Roberts LN, Chitongo PB, et al. More on normal prothrombin times in the presence of therapeutic levels of rivaroxaban-early experience from King's College Hospital. Br J Haematol. 2013;162:717-718.
19. Douxfils J, Tamignia u A, Chatelain B, et al. Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost. 2013;110:723-731.
20. Lindahl TL, Baghaei F, Blixter IF, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371-378.
21. Hapgood G , Butler J, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples. Thromb Haemost. 2013;110: 308-315.
22. Kubitza D, Becka M, Voith B, et al. Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-421.
23. Douxfils J, Dogne JM, Mullier F, et al. Comparison of calibrated dilute thrombin time and aPTT tests wit h LC-MS/MS for the therapeutic monitoring of patients treated with dabigatran etexilate. Thromb Haemost. 2013;110:543-549.
24. Barrett YC, Wang J, Song Y, et al. A randomised assessment of the p harmacokinetic, pharmacodynamic and safety interaction between apixaban and enoxaparin in healthy subjects. Thromb Haemost. 2012;107:916-924.
25. Emanuele RM, Racanelli A, Fareed J. Pharmacokinetics of heparins differing in mean molecular weight using a Xa amidolytic and Heptest clotting method. Ther Drug Monit. 1988;10:153-159.
26. Yin ET, Wessler S, Butler JV. Plasma heparin: a unique, practical, submicrogram-sensitive assay. J Lab Clin Med. 1973;81:298-310.
27. Hoffmann U, Harenberg J, Bauer K, et al. Bioequivalence of subcutaneous and intravenous body-weight-independent high-dose l ow-molecularweight heparin certoparin on anti-Xa, Heptest, and tissue factor pathway inhibitor activity in volunteers. Blood Coagul Fibrinolysis 2002;13: 289-296.
28. Jeske WP, Walenga JM, Samama MM, et al. Functionality of fondaparinux (pentasaccharide) depends on clinical antithrombin levels. Blood Coagul Fibrinolysis. 2011;22:206-210.
29. Harenberg J, Jeschek M, Acker M, et al. Effec ts of low-molecular-weight dermatan sulfate on coagulation, fibrinolysis and tissue factor pathway inhibitor in healthy volunteers. Blood Coagul Fibrinolysis. 1996;7:49-56.
30. Kubitza D, Becka M, Muck W, et al. Pharmacodynamics and pharmacokinetics during the transition from warfarin to rivaroxaban: a randomized study in healthy subjects. Br J Clin Pharmacol. 2014;78:353-363.
31. Mueck W, Lensing A W, Agnelli G, et al. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention. Clin Pharmacokinet. 2011;50:675-686.
32. Miyares MA, Davis K. Newer oral anticoagulants: a review of laboratory monitoring options and reversal agents in the hemorrhagic patient. Am J Health Syst Pharm. 2012;69:1473-1484.
33. Dempfle CE, Zharkowa U, Elmas E, et al. Heptest-STAT, a new assay for monitoring of low-molecular-weight heparins, is not influenced by pregnancy-related changes of blood plasma. Thromb Haemost. 2009;102: 1001-1006.
34. Harenberg J, Giese C, Marx S, et al. Determination of dabigatran in human plasma samples. Semin Thromb Hemost. 2012;38:16-22.
35. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449-1457.
36. Samama MM, Guinet C , Le Flem L, et al. Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis 2013;35:140-146.
37. Walenga JM, Hoppensteadt D, Koza M, et al. Comparative studies on various assays for the laboratory evaluation of r-hirudin. Semin Thromb Hemost. 1991;17:103-112.
38. Asmis LM, Alberio L, Angelillo-Scherrer A, et al. Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories. Thromb Res. 2012;129:492-498.
39. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379-387.
40. Harenberg J, Giese C, Dempfle CE, et al. Monitoring of heparin and low molecular weight heparin with capillary and venous whole blood. Thromb Haemost. 1988;60:377-381.
41. Hellstern P, Bach J, Simon M, et al. Heparin monitoring during cardiopulmonary bypass surgery using the one-step point-of-care whole blood anti-factor-Xa clotting assay heptest-POC-Hi. J Extra Corpor Technol. 2007;39:81-86.
42. Hansen R, Koster A, Kukucka M, et al. A quick anti-Xa-Activity-based whole blood coagulation assay for monitoring unfractionated heparin during cardiopulmonary bypass: a pilot investigation. Anesth Analg. 2000; 91:533-538.